Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 0.42 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810841 | 0.93 | CCR3 (0.44) | DRD4CCR3DRD2HTR2AHRH1 | |
| SCHEMBL1809670 | 0.90 | CCR3 (0.41) | DRD4CCR3DRD2HTR2AMEN1 | |
| SCHEMBL1807893 | 0.88 | DRD4 (0.47) | DRD4CCR3HRH1 | |
| SCHEMBL1807937 | 0.85 | DRD4 (0.46) | DRD4CCR3DRD2MEN1KMT2A | |
| SCHEMBL1810330 | 0.85 | DRD4 (0.48) | DRD4CCR3MEN1KMT2AHRH1 | |
| SCHEMBL1808009 | 0.83 | DRD4 (0.44) | DRD4CCR3KCNH2 | |
| SCHEMBL1809493 | 0.81 | CCR3 (0.49) | DRD4CCR3DRD2HRH1KCNH2 | |
| SCHEMBL1809577 | 0.81 | CCR3 (0.49) | DRD4CCR3DRD2HTR2AMEN1 | |
| SCHEMBL1809572 | 0.81 | CCR3 (0.49) | DRD4CCR3DRD2HTR2AMEN1 | |
| SCHEMBL1809648 | 0.80 | DRD4 (0.47) | DRD4CCR3DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | DRD4 768/4885CCR3 1/4885DRD2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.